<div id="readability-page-1"><div><p><span>Singel Stina, Vice President of Ascendis Pharma A/S [ASND], filed a Form 144 on December 1, 2025 with the Securities and Exchange Commission proposing to sell restricted securities:</span></p><div><table><tbody><tr><td><span>Approximate Date Of Sale</span></td><td><span>12/1/25</span></td></tr><tr><td><span>Shares</span></td><td><span>218</span></td></tr><tr><td><span>Broker</span></td><td><span>Merrill Lynch &amp; Co Inc</span></td></tr></tbody></table></div><p><span>Prior to the sale of restricted stock, owners must file a Form 144 with the SEC.  Upon submission of the filing to the SEC the owner is permitted to sell the shares, or any fraction thereof, within 90 days.</span></p><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

ASND

<p>Singel Stina, Vice President of Ascendis Pharma A/S, filed a Form 144 with the SEC on December 1, 2025, to sell 218 restricted shares through Merrill Lynch & Co Inc. The sale can occur within 90 days of filing.</p>

VP Singel Files To Sell 218 Of Ascendis Pharma A/S [ASND]